A phase 2, open-label, multi-center study to evaluate the efficacy and safety of 99mTc-TRODAT-1 SPECT to detect Parkinson’s disease

• Published in: Annals of nuclear medicine 2020, Vol.34 (1), p.31-37
• Main Authors: Sun, Yu, Liu, Congjin, Chen, Zhengping, Li, Biao, Lv, Zhongwei, Wang, Jian, Lou, Jingjing, Tang, Jie, Wang, Yuankai, Zhang, Guangming, Liu, Xingdang
• Format: Article
• Language: English
• Subjects: Cerebellum; Disease control; Evaluation; Imaging; Medical diagnosis; Medicine; Medicine & Public Health; Movement disorders; Neostriatum; Neurodegenerative diseases; Nuclear Medicine; Original Article; Parkinson's disease; Radioactive tracers; Radiology; Safety; Sensitivity analysis; Single photon emission computed tomography
• ISSN: 0914-7187; 1864-6433
• DOI: 10.1007/s12149-019-01412-2

Objectives To assess the efficacy and safety of 99m Tc-TRODAT-1 SPECT in diagnosing Parkinson’s disease (PD). Methods 99m Tc-TRODAT-1 SPECT imaging was performed in 34 healthy controls and 96 PD patients 2.5 h later after injection. The striatal image was evaluated visually and semi-quantitively. Sensitivity and specificity of 99m Tc-TRODAT-1 SPECT were analyzed according to Hoehn and Yahr scale (HYS). Based on HYS, the PD patients were divided into mild (HYS 1–2) and moderate (HYS 3–5) groups. The uptake ratios of striatum (ST) and cerebellum (CB) in contralateral, ipsilateral and bilateral striatum in different groups were calculated and analyzed. The safety was assessed. Results The sensitivity and specificity of 99m Tc-TRODAT-1 SPECT to discriminate PD patients from healthy subjects were 98.96% and 94.12% and it has perfect agreement with HYS ( κ  = 0.94, p